Add like
Add dislike
Add to saved papers

Rod-like MSN@Au Nanohybrids modified supermolecular photosensitizer for NIRF/MSOT/CT/MR Quadmodal Imaging Guided Photothermal/Photodynamic Cancer Therapy.

Recently, rod-like nanomaterials with specific aspect ratio (AR) for efficient cellular uptake have received enormous attention. For functional nanomaterials, such as photothermal agents, large surface areas for their rod-shape exterior that increase the amount of light absorbed would lead to the higher absorption coefficient as well as drug loading property. In this project, we coated rod-like mesoporous silica with gold nanoshell (MSNR@Au hybrid), modifying with ultrasmall gadolinium (Gd) chelated supramolecular photosensitizers TPPS4 (MSNR@Au-TPPS4(Gd)), which could be applied to near-infrared fluorescence (NIRF) / multispectral optoacoustic tomography (MSOT) / computed tomography (CT) / magnetic resonance (MR) imaging and imaging guided remotely controlled PTT/PDT combined antitumor therapy. Gold nanoshell, as a perfect PTT agent, was used to assemble the rod-like mesoporous silica nanoparticles with larger superficial area and higher drug loading, thus obtaining MSNR@Au hybrid. HS-β-CD, which was used as the host, was adsorbed on gold nanoshell (MSNR@Au-β-CD) to link TPPS4(Gd) through host-guest reaction, thus forming CD-TPPS4 supramolecular PSs (supraPSs). Compared with conventional PSs, supraPSs had the host screens, which could reduce the self-aggregation of the TPPS4, and consequently generate 1O2 with high-efficiency. The quad-modal imaging in vivo of MSNR@Au-TPPS4(Gd) nanoparticles revealed that an intensive tumor uptake effect after injection. In vivo antitumor efficacy further testified that the synergistic therapy, which was more efficient than any other mono-therapy, exhibited an excellent tumor inhibition therapeutic effect. As a result, it's encouraged to further explore multifunctional theranostic nanoparticles based of gold shells for cancer combination therapy.

Full text links

We have located links that may give you full text access.
Can't access the paper?
Try logging in through your university/institutional subscription. For a smoother one-click institutional access experience, please use our mobile app.

Related Resources

For the best experience, use the Read mobile app

Mobile app image

Get seemless 1-tap access through your institution/university

For the best experience, use the Read mobile app

All material on this website is protected by copyright, Copyright © 1994-2024 by WebMD LLC.
This website also contains material copyrighted by 3rd parties.

By using this service, you agree to our terms of use and privacy policy.

Your Privacy Choices Toggle icon

You can now claim free CME credits for this literature searchClaim now

Get seemless 1-tap access through your institution/university

For the best experience, use the Read mobile app